The GMRF Clinical Trials Unit is currently recruiting for the following clinical trials in general oncology:
Protocol: SUPLEXA-101 (PI: Dr Jeffrey Goh)
Protocol Title: A Phase 1, First-in-Human, Open-label Single Agent Study of SUPLEXA Therapeutic Cells in Patients with Metastatic Solid Tumours and Haematologic Malignancies
Lay Title: Study of SUPLEXA in Patients with Metastatic Solid Tumours and Haematologic Malignancies
Click here for more information
PROTOCOL: MDNA11-01 (PI: DR Victoria atkinson)
Protocol Title: A Phase 1/2 Open Label, Dose Escalation and Expansion Study of MDNA11, IL-2 Superkine, Administered Alone or in Combination with Immune Checkpoint Inhibitor in Patients with Advanced Solid
Lay Title: Early Phase IL-2 Superkine with and without Immune checkpoint Inhibitor in advanced solid tumour patients.
Click here for more information
Protocol: CK301-101 (PI: Dr Margaret McGrath) (Cohort 7 only CSCC)
Protocol Title: A Phase 1, Open-label, Multicenter, Dose-escalation Study of CK-301 Administered Intravenously as a Single Agent to Subjects With Advanced Cancers
Lay Title: Phase 1 Study of CK-301 (Cosibelimab) as a Single Agent in Subjects With Advanced Cancers
Click here for more information
PROTOCOL: MK-7902-009 (PI: DR MARGARET MCGRATH)
Short Title: LEAP-009/ Relapsed/Metatstatic Head and Neck Squamous Cell Carcinoma
Protocol Title: A Phase 2, Randomized, Open-label Three-arm Clinical Study to Evaluate the Safety and Efficacy of Lenvatinib (E7080/MK-7902) in Combination With Pembrolizumab (MK-3475) Versus Standard of Care Chemotherapy and Lenvatinib Monotherapy in Participants With Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (R/M HNSCC) That Have Progressed After Platinum Therapy and Immunotherapy
Lay Title: Lenvatinib (E7080/MK-7902) in Combination With Pembrolizumab (MK-3475) vs. Standard Chemotherapy and Lenvatinib Monotherapy in Participants With Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma That Progressed After Platinum Therapy and Immunotherapy
Click here for more information
PROTOCOL: KOM-PAX1-002 (PI: DR MARGARET MCGRATH)
Protocol Title: A Phase 2, open-label study of orally administered PAX-1 in combination with standard of care treatment in patients with newly diagnosed or recurrent glioblastoma
Lay Title: A study of PAX-1 in combination with standard of care treatment in patients with newly diagnosed or recurrent glioblastoma